Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward?

Author： Lazzeri Stefano   Nardi Marco   Bocci Guido  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.11, 2013-08, pp. : 1239-1242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

An update on the pharmacotherapy of neovascular age-related macular degeneration

By Freund K Bailey   Mrejen Sarah   Gallego-Pinazo Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1017-1028

Informa Healthcare

Access to resources Recommend Favorite

Neovascular Age-Related Macular Degeneration: Potential Therapies

By Chappelow Aimee V.   Kaiser Peter K.  

Drugs, Vol. 68, Iss. 8, 2008-01 ,pp. : 1029-1036

Adis International

Access to resources Recommend Favorite

Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration

By Parmeggiani Francesco   Gemmati Donato   Costagliola Ciro   Sebastiani Adolfo   Incorvaia Carlo  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 81-95

Future Medicine

Access to resources Recommend Favorite

Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration

By Ohr Matthew   Kaiser Peter K  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 585-591

Informa Healthcare

Access to resources Recommend Favorite

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

By Moshfeghi Andrew A   Puliafito Carmen A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 671-682

Informa Healthcare

Access to resources Recommend Favorite